Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has scheduled its third quarter 2024 financial results release for November 12, 2024, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone (1-888-596-4144 for domestic, +1-646-968-2525 for international callers, conference ID: 3650755) or through a webcast available on the company's website.
Iridex (NASDAQ: IRIX), fornitore di sistemi medicali basati su laser per il trattamento del glaucoma e delle malattie retiniche, ha programmato il rilascio dei suoi risultati finanziari del terzo trimestre 2024 per il 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una teleconferenza alle 14:00 PT / 17:00 ET lo stesso giorno. Gli investitori possono partecipare via telefono (1-888-596-4144 per chiamate nazionali, +1-646-968-2525 per chiamate internazionali, ID conferenza: 3650755) o tramite un webcast disponibile sul sito web dell'azienda.
Iridex (NASDAQ: IRIX), proveedor de sistemas médicos basados en láser para el tratamiento del glaucoma y enfermedades de la retina, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el 12 de noviembre de 2024, después del cierre del mercado. La empresa realizará una conferencia telefónica a las 2:00 p.m. PT / 5:00 p.m. ET el mismo día. Los inversores pueden unirse por teléfono (1-888-596-4144 para llamadas nacionales, +1-646-968-2525 para llamadas internacionales, ID de conferencia: 3650755) o a través de un webcast disponible en el sitio web de la empresa.
Iridex (NASDAQ: IRIX), 녹내장 및 망막 질환 치료를 위한 레이저 기반 의료 시스템의 공급업체는 2024년 3분기 재무 결과 발표를 2024년 11월 12일, 시장 마감 후로 예정하고 있습니다. 회사는 같은 날 오후 2시 PT / 오후 5시 ET에 컨퍼런스 콜을 개최할 예정입니다. 투자자들은 전화(국내: 1-888-596-4144, 국제: +1-646-968-2525, 회의 ID: 3650755)로 참여하거나 회사 웹사이트에서 제공되는 웹캐스트를 통해 참여할 수 있습니다.
Iridex (NASDAQ: IRIX), fournisseur de systèmes médicaux basés sur laser pour le traitement du glaucome et des maladies rétiniennes, a programmé la publication de ses résultats financiers du troisième trimestre 2024 pour le 12 novembre 2024, après la fermeture du marché. L'entreprise tiendra une conférence téléphonique le même jour à 14h00 PT / 17h00 ET. Les investisseurs peuvent rejoindre par téléphone (1-888-596-4144 pour les appels nationaux, +1-646-968-2525 pour les appelants internationaux, identifiant de conférence : 3650755) ou via un webcast disponible sur le site internet de l'entreprise.
Iridex (NASDAQ: IRIX), Anbieter von laserbasierten Medizinsystemen zur Behandlung von Glaukom und Netzhauterkrankungen, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für den 12. November 2024, nach Marktschluss, angesetzt. Das Unternehmen wird am selben Tag um 14:00 Uhr PT / 17:00 Uhr ET eine Telefonkonferenz abhalten. Investoren können telefonisch teilnehmen (1-888-596-4144 für inländische Anrufe, +1-646-968-2525 für internationale Anrufer, Konferenz-ID: 3650755) oder über einen Webcast, der auf der Unternehmenswebsite verfügbar ist.
- None.
- None.
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for international callers, using conference ID: 3650755. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex (IRIX) release Q3 2024 earnings?
How can I listen to Iridex (IRIX) Q3 2024 earnings call?
What time is Iridex (IRIX) Q3 2024 earnings call?
